India Bears 70% of South Asia’s Childhood Leukaemia Burden, Landmark Lancet Study Reveals

NEW DELHI — India accounts for nearly 70% of all childhood leukaemia cases in South Asia, according to a landmark population-based analysis published in The Lancet Regional Health – Southeast Asia. The comprehensive study highlights stark regional disparities in diagnosis, treatment access, and cancer registration across the South Asian Association for Regional Cooperation (SAARC) nations.

The analysis estimates that in 2022, there were 37,716 new childhood cancer diagnoses and 17,698 deaths across SAARC member states. India alone contributed 25,939 of those new cases. Across every country evaluated, leukaemia emerged as the single most common pediatric malignancy, accounting for 35% to 50% of all childhood cancer diagnoses.

       South Asian Childhood Cancer Burden (2022 GLOBOCAN Estimates)
 ┌────────────────────────────────────────────────────────────────────────┐
 │  Total SAARC New Cases: 37,716                                         │
 │  ■ India: 25,939 cases (68.8%)                                         │
 │  ■ Other SAARC Nations: 11,777 cases (31.2%)                           │
 ├────────────────────────────────────────────────────────────────────────┤
 │  Total SAARC Deaths: 17,698                                            │
 └────────────────────────────────────────────────────────────────────────┘

While these numbers present a sobering picture, public health experts emphasize that India’s dominant share of cases reflects its massive pediatric population rather than an inherently higher biological susceptibility. However, the study exposes deep structural hurdles within regional healthcare infrastructure that delay diagnosis and fragment patient care.

Regional Disparities: Incidence vs. Mortality

To evaluate the true scope of the disease, researchers analyzed data from Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka using GLOBOCAN 2022 estimates.

The findings reveal pronounced differences in both cancer incidence and survival outcomes across borders:

“The stark contrast in mortality rates across South Asia reflects not merely biological realities, but the operational strength of individual health systems,” noted the study authors. “The time it takes for a family to navigate from initial symptom onset to a specialist referral often dictates whether a child survives.”

Unpacking India’s Burden: Demographics and Systemic Gaps

India’s prominent position in the data is primarily driven by demographics—the country is home to over 20% of the world’s pediatric population. However, medical experts caution against looking solely at population size.

In India, national registries frequently track new diagnoses (incidence) rather than following long-term active cases or survivorship. This creates blind spots in understanding true disease prevalence and long-term treatment adherence.

Furthermore, researchers note that because these findings rely on epidemiological modeling, the actual number of children living with leukaemia may be significantly higher due to widespread underdiagnosis in rural and economically disadvantaged districts.

Biological Context: Focus on Acute Lymphoblastic Leukaemia

Childhood leukaemia is not a single uniform disease. In India:

• Leukaemia accounts for 30% to 40% of all pediatric cancer diagnoses.

• Acute Lymphoblastic Leukaemia (ALL) constitutes roughly 70% to 75% of those blood cancer cases.

• Acute Myeloid Leukaemia (AML) and other rarer forms account for the remainder.

Understanding these subtypes is vital because Acute Lymphoblastic Leukaemia carries a cure rate exceeding 80–90% in high-income countries when diagnosed early and treated with standardized chemotherapy protocols. In South Asia, however, treatment abandonment, late-stage presentation, and secondary infections continue to depress overall survival rates.

Clinical Perspectives: Bridging the Early Detection Gap

Clinicians stress that the high numbers reported in the study do not signal a sudden surge in disease incidence, but rather an improving ability to catch and log cases that previously went undetected.

“Leukaemia remains considerably more common in India and the Bengal region than in Western nations,” explains Dr. Pritam Singha Roy, Consultant Pediatric Oncologist at Tata Medical Centre. “Over the past decade, improved diagnostic tools, growing public awareness, and targeted government healthcare initiatives have enabled us to identify far more affected children who previously would have slipped through the cracks.”

However, delayed presentation remains a persistent obstacle.

“Low awareness among both the public and primary healthcare workers remains a primary driver of late diagnosis,” says Dr. Narendra Agarwal, a haematologist and bone marrow transplant physician at Rajiv Gandhi Cancer Institute & Research Centre. “While treatment facilities and survival outcomes have advanced substantially across India, we are still seeing too many children arrive at tertiary centers with advanced disease.”

           The Pathway to Improved Pediatric Cancer Survival
 ┌─────────────────┐     ┌──────────────────┐     ┌──────────────────┐
 │ Early Symptom   │ ──> │ Prompt Primary   │ ──> │ Rapid Tertiary   │
 │ Recognition     │     │ Medical Evaluation│    │ Referral & Care  │
 └─────────────────┘     └──────────────────┘     └──────────────────┘

Distinguishing Warning Signs from Everyday Illnesses

A fundamental challenge in pediatric oncology is that early blood cancer symptoms frequently mimic routine childhood infections. Unlike adult cancers, which are often linked to preventable lifestyle factors like smoking or environmental exposures, childhood cancers arise predominantly from non-preventable genetic mutations. Consequently, symptom vigilance is the primary tool for early detection.

Medical professionals advise parents and caregivers to seek medical evaluation if a child exhibits persistent or unexplained symptoms, including:

• Unexplained, Recurrent Fever: Low-grade or high-grade fever that fails to resolve with standard antibiotics.

• Progressive Pallor and Fatigue: Unusual tiredness, lethargy, or unusually pale skin, lips, or nail beds (signs of anemia).

• Unusual Bleeding or Bruising: Frequent nosebleeds, bleeding gums, or unexplained purple/red spots (petechiae) on the skin.

• Persistent Bone or Joint Pain: Pain that causes a child to limp or wake up crying at night.

• Swollen Lymph Nodes or Abdomen: Painless swelling in the neck, armpits, groin, or abdominal fullness caused by an enlarged spleen or liver.

Public Health Action: The Path Forward

The findings from The Lancet Regional Health present a clear call to action for healthcare policymakers across South Asia. Improving pediatric cancer survival requires structural reforms that address the entire continuum of care:

1. Strengthening Subregional Cooperation: Harmonizing cancer registries across SAARC countries to collect accurate, real-time survival data.

2. Training Frontline Healthcare Workers: Equipping primary care doctors and rural health workers to recognize early red-flag symptoms.

3. Decentralizing Pediatric Oncology Infrastructure: Expanding specialty diagnostic and treatment units beyond major metropolitan hubs to reduce travel friction for rural families.

4. Financial and Nutritional Support: Establishing holistic care models that provide financial assistance and nutritional support to prevent families from abandoning treatment midway.

By establishing integrated referral pathways and expanding access to timely diagnostics, public health leaders believe South Asia can close the survival gap and ensure that a childhood cancer diagnosis is no longer a sentence of compromised survival.

References

1. ET HealthWorld / Economic Times Health. India accounts for 70% of South Asia’s childhood leukaemia cases: Study. Published August 2, 2026. Reporting expert commentaries from Dr. Pritam Singha Roy (Tata Medical Centre) and Dr. Narendra Agarwal (Rajiv Gandhi Cancer Institute & Research Centre).

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.